The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way

Prostate

Volumn 73, Issue 3, 2013, Pages 267-277

  Mediwala, Sanjay N ^a,b   Sun, Huiying ^a,b   Szafran, Adam T ^a   Hartig, Sean M ^a   Sonpavde, Guru ^a,b   Hayes, Teresa G ^a,b   Thiagarajan, Perumal ^a,b   Mancini, Michael A ^a   Marcelli, Marco ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

AR V7; castration resistant prostate cancer; PI3K

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR V7; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE INHIBITOR; RNA; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG; WORTMANNIN;

ARTICLE; CANCER CELL; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG INHIBITION; GENE EXPRESSION; GENE TECHNOLOGY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REPORTER GENE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANDROSTADIENES; CASTRATION; CELL LINE, TUMOR; CHROMONES; DISEASE PROGRESSION; FORKHEAD TRANSCRIPTION FACTORS; GENETIC VARIATION; HUMANS; MALE; MORPHOLINES; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84872808630     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22566     Document Type: Article

References (51)

1. Siegel R, Ward E, Brawley O, Jemal A,. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: A Cancer Journal For Clinicians 2011; 61: 212-236.
2. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ,. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002; 62: 1008-1013.
3. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL,. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-39.
4. Nelson WG, Haffner MC, Yegnasubramanian S,. Beefing up prostate cancer Therapy with performance-enhancing (anti-) steroids. Cancer Cell 2011; 20: 7-9.
5. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ,. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008; 68: 5469-5477.
6. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J,. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009; 69: 16-22.
7. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y,. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009; 69: 2305-2313.
8. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR,. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010; 120: 2715-2730.
9. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL,. Inaugural article: Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 2010; 107: 16759-16765.
10. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB,. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011; 17: 5913-5925.
11. Szafran AT, Szwarc M, Marcelli M, Mancini MA,. Androgen receptor functional analyses by high throughput imaging: Determination of ligand, cell cycle, and mutation-specific effects. PLoS ONE 2008; 3: e3605.
12. Marcelli M, Stenoien DL, Szafran AT, Simeoni S, Agoulnik IU, Weigel NL, Moran T, Mikic I, Price JH, Mancini MA,. Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility. J Cell Biochem 2006; 98: 770-788.
13. Nazareth L, Weigel N,. Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 1996; 271: 19900-19907.
14. Ueda T, Bruchovsky N, Sadar MD,. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 2002; 277: 7076-7085.
15. Kozikowski AP, Sun H, Brognard J, Dennis PA,. Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. J Chem Am Soc 2003; 125: 1144-1145.
16. Sherk AB, Frigo DE, Schnackenberg CG, Bray JD, Laping NJ, Trizna W, Hammond M, Patterson JR, Thompson SK, Kazmin D, Norris JD, McDonnel DP,. Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic. Cancer Res 2008; 68: 7475-7483.
17. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA,. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996; 15: 6541-6551.
18. Park J, Leong ML, Buse P, Maiyar AC, Firestone GL, Hemmings BA,. Serum and glucocorticoid-inducible kinase (SGK) is a target of the PI 3-kinase-stimulated signaling pathway. EMBO J 1999; 18: 3024-3033.
19. Szafran AT, Hartig S, Sun H, Szwarc M, Chen Y, Mediwala S, Bell J, McPhaul MJ, Mancini MA, Marcelli M,. Androgen receptor mutations associated with androgen insensitivity syndrome: A high content analysis approach leading to personalized medicine. PLoS ONE 2009; 4: e8179.
20. Biggs WH III, Meisenhelder J, Hunter T, Cavenee WK, Arden KC,. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci USA 1999; 96: 7421-7426.
21. Fan W, Yanase T, Morinaga H, Okabe T, Nomura M, Daitoku H, Fukamizu A, Kato S, Tahayanagi R, Nawata H,. Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. J Biol Chem 2007; 282: 7329-7338.
22. Liu P, Li S, Gan L, Kao TP, Huang H,. A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells. Cancer Res 2008; 68: 10290-10299.
23. Ma Q, Fu W, Li P, Nicosia SV, Jenster G, Zhang X, Bai W,. FoxO1 mediates PTEN suppression of androgen receptor N- and C-terminal interactions and coactivator recruitment. Mol Endocrinol 2009; 23: 213-225.
24. Tang ED, Nunez G, Barr FG, Guan KL,. Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem 1999; 274: 16741-16746.
25. Godowski PJ, Rusconi S, Miesfeld R, Yamamoto KR,. Glucocorticoid receptor mutants that are constitutive activators of transcriptional enhancement. Nature 1987; 325: 365-368.
26. Jenster G, Trapman J, Brinkmann AO,. Nuclear import of the human androgen receptor. Biochem J 1993; 293: 761-768.
27. Marcelli M, Tilley WD, Wilson CM, Griffin JE, Wilson JD, McPhaul M,. Definition of the human androgen receptor gene permits the identification of mutations that cause androgen resistance: Premature termination codon of the receptor protein at amino acid residue 588 causes complete androgen resistance. Mol Endocrinol 1990; 4: 1105-1116.
28. Zhou ZX, Sar M, Simental JA, Lane MV, Wilson EM,. A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2 and carboxyl-terminal sequences. J Biol Chem 1994; 269: 13115-13123.
29. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J,. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 1998; 58: 2720-2723.
30. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parson R,. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer [see comments]. Science 1997; 275: 1943-1947.
31. Nan B, Snabboon T, Unni E, Yuan XJ, Whang YE, Marcelli M,. The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity. J Mol Endocrinol 2003; 31: 169-183.
32. Li P, Nicosia SV, Bai W,. Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells. J Biol Chem 2001; 276: 20444-20450.
33. Sharma M, Chuang WW, Sun Z,. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. J Biol Chem 2002; 277: 30935-30941.
34. Lin HK, Yeh S, Kang HY, Chang C,. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA 2001; 98: 7200-7205.
35. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL,. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011; 19: 575-586.
36. Li P, Lee H, Guo S, Unterman TG, Jenster G, Bai W,. AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol Cell Biol 2003; 23: 104-118.
37. Wu Z, Conaway M, Gioeli D, Weber MJ, Theodorescu D,. Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells. Prostate 2006; 66: 1114-1123.
38. Manin M, Baron S, Goossens K, Beaudoin C, Jean C, Veyssiere G, Verhoeven G, Morel L,. Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells. Biochem J 2002; 366: 729-736.
39. Gao H, Ouyang X, Banach-Petrosky WA, Gerald WL, Shen MM, Abate-Shen C,. Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci USA 2006; 103: 14477-14482.
40. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C,. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008; 118: 3051-3064.
41. Liu P, Cheng H, Roberts TM, Zhao JJ,. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8: 627-644.
42. Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, Vanpatten K, Highstrom L, Pestano GA, Nagle RB,. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 2006; 66: 1203-1212.
43. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS, Sidransky D,. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997; 57: 4997-5000.
44. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR,. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999; 59: 4291-4296.
45. Gray IC, Phillips SM, Lee SJ, Neoptolemos JP, Weissenbach J, Spurr NK,. Loss of the chromosomal region 10q 23-25 in prostate cancer. Cancer Res 1995; 55: 4800-4803.
46. Bedolla R, Prihoda TJ, Kreisberg JI, Malik SN, Krishnegowda NK, Troyer DA, Ghosh PM,. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res 2007; 13: 3860-3867.
47. Schmitz M, Grignard G, Margue C, Dippel W, Capesius C, Mossong J, Nathan M, Giacchi S, Scheiden R, Kieffer N,. Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer 2007; 120: 1284-1292.
48. Marone R, Cmiljanovic V, Giese B, Wymann MP,. Targeting phosphoinositide 3-kinase: Moving towards therapy. Biochim Biophys Acta 2008; 1784: 159-185.
49. Dubrovska A, Elliott J, Salamone RJ, Kim S, Aimone LJ, Walker JR, Watson J, Sauveur-Michel M, Garcia-Echeverria C, Cho CY, Reddy VA, Schultz PG,. Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma. Clin Cancer Res 16: 5692-5702.
50. Posadas EM, Gulley J, Arlen PM, Trout A, Parnes HL, Wright J, Lee MJ, Chung EJ, Trepel JB, Sparreboom, Chen C, Jones E, Steinberg SM, Daniels A, Figg WD, Dahut WL,. A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther 2005; 4: 1133-1137.
51. Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW,. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 2006; 24: 2723-2728.